

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

3DMed

思路迪

3D Medicines Inc.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1244)

VOLUNTARY ANNOUNCEMENT PROPOSED ON-MARKET SHARE REPURCHASE PLAN

This announcement is made by 3D Medicines Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to keep the shareholders of the Company (the “**Shareholders**”) and potential investors informed on the latest plans of the Group.

The board of directors (the “**Board**”) of the Company wishes to announce that the Board has approved a plan (the “**Proposed Share Repurchase Plan**”) to exercise the general mandate to repurchase Shares of the Company (the “**Share Repurchase Mandate**”) that has been granted by the shareholders of the Company to the Board at the annual general meeting (“**AGM**”) of the Company held on June 26, 2023, and the relevant general mandate to repurchases Shares of the Company to be proposed and approved at the Company’s 2024 annual general meeting, in the open market at appropriate timing. Pursuant to the Share Repurchase Mandate, the Company is allowed to repurchase up to 25,605,700 Shares, being 10% of the aggregate number of issued Shares of the Company at the date of AGM on The Stock Exchange of Hong Kong Limited. As at the date of this announcement, no Shares have been repurchased and cancelled under Share Repurchase Mandate. When conducting the Proposed Share Repurchase Plan, the Board will exercise the Share Repurchase Mandate while maintaining a sufficient public float as required under the Rules Governing the Listing of Securities on the Main Board of the Stock Exchange (the “**Listing Rules**”). The approved period for the Proposed Share Repurchase Plan will not be more than twelve months since the date of this announcement.

The Board considers that the current trading price of the Shares does not reflect their intrinsic value and the actual business prospects of the Company. The Board believes the Proposed Share Repurchase Plan and subsequent cancellation of the repurchased Shares can enhance the value of the Shares thereby improving the return to the Shareholders. The Board believes that the Proposed Share Repurchase Plan is in the interests of the Company and the Shareholders as a whole.

The financial position of the Company is solid and healthy. The Board also considers that the Company’s own financial resources would enable it to conduct the Proposed Share Repurchase Plan without affecting the continued development of the Company. Any exercise of the Share Repurchase Mandate under the Proposed Share Repurchase Plan, if and when conducted, will be subject to and in compliance with the articles of association of the Company, the Listing Rules, the Codes on Takeovers and Mergers and Share Buy-backs issued by the Securities and Futures Commission, the laws of the Cayman Islands and all applicable laws and regulations to which the Company is subject to.

As of the date of this announcement, Dr. Gong Zhaolong (“**Dr. Gong**”), being the founder, executive director, chief executive officer, chairman of the Board and a substantial shareholder and the single largest shareholder of the Company, together with Dragon Prosper Holdings Limited, Immunal Medixin US Limited, Immunal Medixin Cino L. Limited and Immunal Medixin Cino Limited, continue to be subject to the lock-up obligations under the Hong Kong underwriting agreement dated November 28, 2022. As of the date of this announcement, the number of Shares deemed to be interested by Dr. Gong is 74,330,404 Shares (representing approximately 28.79% of the total issued share capital of the Company as at the date of this announcement). Please refer to the prospectus of the Company dated November 29, 2022 and the allotment results announcement dated December 14, 2022 for details.

Shareholders of the Company and potential investors should note that, as at the date of this announcement, the Company has not repurchased any Shares under the Proposed Share Repurchase Plan. The exercise of the Share Repurchase Mandate by the Company will be subject to market conditions and will be at the Board’s absolute discretion. There is no assurance of the timing, quantity or price of any Share repurchases or whether or not the Company will make any further repurchases at all. Therefore, Shareholders and potential investors should exercise caution when dealing in the securities of the Company.

By order of the Board
3D Medicines Inc.
Dr. Gong Zhaolong
Chairman of the Board

Hong Kong
October 4, 2023

As at the date of this announcement, the Board of Directors of the Company comprises Dr. GONG Zhaolong as executive Director, Mr. ZHU Pai, Mr. ZHOU Feng and Ms. CHEN Yawen as non-executive Directors, and Dr. LI Jin, Dr. LIN Tat Pang and Mr. LIU Xinguang as independent non-executive Directors.